Salute e Benessere

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; May 5, 2025 – Genmab A/S (Nasdaq: GMAB).On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025.The following transactions were executed under the program from April 28 to May 2, 2025: Trading PlatformNo...
Nasdaq GlobeNewswire
05/05/2025

Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for…

"A growing number of patients with multiple myeloma have been heavily pretreated, have exhausted currently approved therapies, and continue to face disease progression," said Cyril Konto, M.D., President and CEO of IGI. "At IGI, we have long recognized the urgent need for novel treatment options – particularly for patients who have already received first-generation bispecifics or CAR T-cell therapies. Our trispecific candidate is designed to enhance tumor targeting while reducing…
PR Newswire
05/05/2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™…

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product , effective as of April 30, 2025SELARSDI is approvedfor all indicationsmatching the reference productSELARSDI is indicatedfor the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older , and...
Nasdaq GlobeNewswire
05/05/2025

Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™…

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product , effective as of April 30, 2025SELARSDI is approvedfor all indicationsmatching the reference productSELARSDI is indicatedfor the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and pediatric patients 6 years and older , and the...
Nasdaq GlobeNewswire
05/05/2025

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 , and mRNA cancer immunotherapiesPresented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”)Development and commercial preparation for...
Nasdaq GlobeNewswire
05/05/2025

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief…

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE)–BioNTech SE(Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end...
Nasdaq GlobeNewswire
05/05/2025

HAVAS LIFE EXPANDS GLOBAL PRESENCE WITH NEW AGENCY LAUNCH IN MIDDLE EAST

"This launch underscores our commitment to expanding Havas Life's footprint in regions where healthcare innovation is thriving—and where our clients are rapidly investing in multi-country growth across the Middle East," stated Charles Houdoux, CEO – APAC & LATAM of Havas Health Network. "With Carlo's leadership and our team's expertise, we're poised to deliver creative solutions that truly transform how healthcare brands connect with their audiences." "This launch…
PR Newswire
05/05/2025

Trading in GN Store Nord shares by board members, executives and associated…

GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them. Details of the person discharging managerial responsibilities/person closely associated NameSøren Jelert Reason for the notification Position/statusChief Financial OfficerInitial...
Nasdaq GlobeNewswire
05/05/2025

Safe Life Fortifies European Market Presence with Acquisition of France DAE

"We are excited to welcome France DAE to the Safe Life family," says Jimmy Eriksson, CEO of Safe Life. "Their strong market position, experienced team, and customer-first philosophy align perfectly with our values. This acquisition is another important step toward our mission of making life-saving technology more accessible across Europe." "We are excited to welcome France DAE to the Safe Life family," says Jimmy Eriksson, CEO of Safe Life. "Their strong market…
PR Newswire
05/05/2025

Telix's Illuccix® PSMA-PET Imaging Agent Approved in the Czech Republic

Illuccix, after radiolabelling with gallium-68, is indicated in the Czech Republic for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Illuccix, after radiolabelling with gallium-68, is indicated in theCzech Republicfor the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: ...
PR Newswire
05/05/2025

How Robotic Vial Washing and Filling Machines Are Transforming the…

Transparency Market Research
05/05/2025

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT APRIL 2025

Accumulated revenue for January – April 2025 increased by 58 % to SEK 979.4 (620.7) million. Accumulated revenue for January –April 2025increased by 58 % toSEK 979.4(620.7) million. Revenues were distributed as follows: Countries in regions: For more information: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700,www.zinzino.com Pictures for publication free of charge: [email protected] Certified Adviser: Carnegie Investment Bank AB (publ.) This...
PR Newswire
05/05/2025

Inventiva secures the €116 million second tranche of its structured financing of…

Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.Daix (France), New York City (New York, United States), May 5, 2025– Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”) and other...
Nasdaq GlobeNewswire
05/05/2025

Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating…

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include:An association between increased circulating tumor mutational...
Nasdaq GlobeNewswire
05/05/2025

GENFIT to Present Latest ACLF Research at EASL Congress 2025

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 5, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces its participation at the European Association for the Study of the Liver (EASL) Annual Congress 2025 with six posters presenting the latest research in ACLF and multiple events highlighting the growing importance of ACLF within...
Nasdaq GlobeNewswire
05/05/2025

Dawn Health Secures €11.5 Million to Scale Platform & Product Suite for Next-Gen…

The Dawn Platform and Product Suite empower pharma companies, patients, and healthcare professionals to improve outcomes and patient care by leveraging advanced capabilities in AI, data, evidence generation, clinical integrations, personalization, and connected health. By improving both data collection and analytics, these capabilities ultimately benefit patients and pharma companies alike, positioning the Dawn Platform as the foundation for therapy companions, disease management programs, and…
PR Newswire
05/05/2025

Roquette Announces a New Organization following the Acquisition of IFF Pharma…

Roquette Announces a New Organization following the Acquisition of IFF Pharma SolutionsThe company launches two renewed and strengthened Business Groups, and appoints their new leadersLille, May 5, 2025 –Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces today a new organization following the successful acquisition of IFF Pharma Solutions announced on May 1. The new organization is designed to enhance...
Nasdaq GlobeNewswire
05/05/2025

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific…

Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors ZURICH, SWITZERLAND, May 5, 2025 --VERAXA Biotech AG(“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp.(NASDAQ:VACH, “Voyager”), announced today a co-discovery alliance withOmniAb, Inc.(NASDAQ: OABI, “OmniAb”) for the development of a novel bispecific...
Nasdaq GlobeNewswire
05/05/2025

Canton Fair Chronicles a Decade of Growth in the Global Pet Economy

The 137th Canton Fair marked the fifth appearance of Puyuan (Dalian) Pet Products Co., Ltd., which values the event for its unique advantages over industry-specific exhibitions. May Wu, Puyuan's Operation Manager, noted that the Fair attracts a more diverse group of buyers, enabling access to procurement teams that are often absent at niche trade shows. This exposure has opened doors to new customer segments and led to larger orders from major retailers and supermarkets. The 137th Canton Fair...
PR Newswire
04/05/2025

IBA launches QUASAR® GRID3D Advantage Image Distortion Analysis System

New standard in the Quality Assurance of image distortion for MR guided radiation therapy and MR simulation in planningLouvain-la-Neuve, Belgium, 3 May 2025– IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a global leading provider of dosimetry and quality assurance (QA) solutions, today announces the launch of itsQUASAR ® GRID 3D Advantage Image Distortion Analysis Systemat the European Society for Radiotherapy and Oncology...
Nasdaq GlobeNewswire
03/05/2025

IBA launches myQA Blue Phantom³ for radiation therapy quality assurance

Fastest automatic levelling offering on the marketSeamless integration with all linear acceleratorsLouvain-la-Neuve, Belgium, 2 May 2025– IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and a leading provider of dosimetry and quality assurance (QA) solutions, announces the launch of myQA Blue Phantom³ at the European Society for Radiotherapy and Oncology (ESTRO) 2025 annual congress in Vienna, Austria. This innovative solution is set to...
Nasdaq GlobeNewswire
02/05/2025

Filter Media Market Expands Amid Rising Demand in Industrial and Biomedical…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-4F877/Global_Filter_Media_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-4F877/Global_Filter_Media_Market Major Factors Driving the Growth of Filter Media Market: The filter media market continues to grow steadily, supported by expanding applications across industries ranging from biomedical and automotive to food processing and industrial manufacturing. The rising...
PR Newswire
02/05/2025

CARBIOS files its 2024 Universal Registration Document

Clermont-Ferrand (France), May 2, 2025 (6:00 pm CEST).CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announcest o its shareholders and the financial community that its 2024 Universal Registration Document including the annual report, the management report and the report on corporate governance was filed with the French Financial Market Authority (Autorité des...
Nasdaq GlobeNewswire
02/05/2025

Sanofi: Information concerning the total number of voting rights and shares -…

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of theCode de commerce(the French Commercial Code) and article 223-16 of theRèglement général de l'Autorité des Marchés Financiers(Regulation of the French stock market authority) Sanofi a Frenchsociété anonymewith a registered share capital of €2,452,461,656 Registered office : 46, avenue de la Grande Armée - 75017 Paris - France Registered at the Paris...
Nasdaq GlobeNewswire
02/05/2025
Altri  Comunicati